SUMMARY OF STUDENT EVALUATIONS AY 2019/2020, Class of 2022

Prepared by:

Andrea Braundmeier-Fleming, Ph.D. Associate Professor, Department of Medical Microbiology, Immunology and Cell Biology, Department of Obstetrics and Gynecology Year Two Curriculum Director, Office of Education and Curriculum

10/15/21

EXECUTIVE SUMMARY

- SIU SOM's second year (Y2) of medical school is comprised of four units: Hematology/Immunology/Infectious Disease (HII), Cardio/Respiratory/Renal (CRR), Neural/Muscular/Behavioral (NMB), and Endocrine/Reproduction/Gastro (ERG).
- There were 74 total students in the Y2 cohort in AY 2019/2020
- Y2 students were asked to evaluate each unit as a whole. These are big picture data points.

Unit	Response Rate (out of 74 students)	Quality Rating (out of 5.0)	Time Devoted to Learning Activities (out of 5.0)
HII	69%	4.06	3.27
CRR	67.5%	3.98	3.74
NMB	29.7%	3.82	3.81
ERG	43.2%	3.5	3.44

- Things we learned:
 - Overall our response rate from the students decreases as we move into the later units of the academic calendar.
 - Overall the quality rating of units is favorable but declines as the curricular year approaches Step 1 dedication time.
 - Students feel on average about the amount of time they are given to complete unit activities. In HII (first unit) there is a wealth of information and students feel overwhelmed. In ERG (last unit) students feel overwhelmed because their study time is split between the curricular learning issues and preparation for Step 1.
 - It would be very interesting if we could place the ERG unit earlier in the academic year and see if it affects the quality rating score.
 - In the last part of this academic year is when the curriculum was dramatically affected by the pandemic. At the very beginning of ERG the curriculum needed to pivot to deliver tutor groups, resource sessions and also doctoring activities in a remote virtual environment. It was a hard adjustment both for the unit team and also the students. Overall, we made it through and learned some very valuable lessons about our curriculum and how to make adaptations that did not sacrifice curricular value. It was not easy but we managed to keep the curriculum running during the pandemic.

SUMMARY of STUDENT EVALUATIONS BY Y2 UNIT (Bigger Picture)

	Responses Rate (out of 74)	Quality Rating (out of 5)
Hematology/Immunology/Infectious Disease (First Un	it of Calendar Year N	1id Aug-Mid Oct)
In general, this unit was successful in meeting its goals.	69%	4.06
The unit schedule had an appropriate amount of time	69%	3.26
devoted to learning activities (self-directed		
learning/studying, resource sessions, clinical		
experiences, doctoring mentor clinics, CAM, doctoring		
sessions).		
The Unit Directors were accessible and available.	69%	4.25
Doctoring Director (Y2)/Unit Nurse Educator (Y2) was	69%	4.53
accessible and available.		
Clinical skills session educators/observers	69%	4.55
(Y2)/assigned nurse educator (Y2) was a good resource		
for learning.		
The End-of-Unit Assessment provided a fair	69%	3.78
assessment of the knowledge, clinical skills, and		
professional attitudes/behaviors I developed during		
the unit.		
Average	69%	4.07

Cardio/Respiratory/Renal (CRR) (Second Unit of Calend	dar Year Mid Oct-Dec	:)
In general, this unit was successful in meeting its goals.	67.5%	3.98
The unit schedule had an appropriate amount of time	67.5%	3.74
devoted to learning activities (self-directed		
learning/studying, resource sessions, clinical		
experiences, doctoring mentor clinics, CAM, doctoring		
sessions).		
The Unit Directors were accessible and available.	67.5%	3.98
Doctoring Director (Y2)/Unit Nurse Educator (Y2) was	67.5%	4.46
accessible and available.		
Clinical skills session educators/observers	67.5%	4.72
(Y2)/assigned nurse educator (Y2) was a good resource		
for learning.		
The End-of-Unit Assessment provided a fair	67.5%	3.84
assessment of the knowledge, clinical skills, and		
professional attitudes/behaviors I developed during		
the unit.		
Average	44%	4.12

Neuro/Muscular/Behavioral (Third Unit of Calendar Ye	ear January-Mid Mar	ch)
In general, this unit was successful in meeting its goals.	29.7%	3.82
The unit schedule had an appropriate amount of time	29.7%	3.81
devoted to learning activities (self-directed		
learning/studying, resource sessions, clinical		
experiences, doctoring mentor clinics, CAM, doctoring		
sessions).		
The Unit Directors were accessible and available.	29.7%	4
Doctoring Director (Y2)/Unit Nurse Educator (Y2) was	29.7%	4.43
accessible and available.		
Clinical skills session educators/observers	29.7%	4.52
(Y2)/assigned nurse educator (Y2) was a good resource		
for learning.		
The End-of-Unit Assessment provided a fair	29.7%	2.81
assessment of the knowledge, clinical skills, and		
professional attitudes/behaviors I developed during		
the unit.		
Average	29.7%	3.89

Endocrine/Reproduction/Gastro (Fourth Unit of Calenc	lar Year Mid March-N	/lay)
In general, this unit was successful in meeting its goals.	43.2%	3.22
The unit schedule had an appropriate amount of time	43.2%	3.44
devoted to learning activities (self-directed		
learning/studying, resource sessions, clinical		
experiences, doctoring mentor clinics, CAM, doctoring		
sessions).		
The Unit Directors were accessible and available.	43.2%	3.66
Doctoring Director (Y2)/Unit Nurse Educator (Y2) was	43.2%	4.41
accessible and available.		
Clinical skills session educators/observers	43.2%	4.47
(Y2)/assigned nurse educator (Y2) was a good resource		
for learning.		
The End-of-Unit Assessment provided a fair	43.2%	2.47
assessment of the knowledge, clinical skills, and		
professional attitudes/behaviors I developed during		
the unit.		
Average	43.2%	3.61

SUMMARY OF STUDENT EVALUATIONS BY REQUIRED Y2 LEARNING EXPERIENCE BY UNIT (Smaller Picture)

Торіс	Reporting	Score
Bacterial Structure and Morphology	14	3.93
Innate Immunity to Bacterial Infections	14	4.71
Bacteril Virulence Factors	11	4.09
Staphyloccus	11	4.09
Microbial Genetics	10	4.1
Acquired Immunity	9	4.44
Epidemiology of Infectious Diseases	5	4.4
Integrated Clinical Case Conference	8	4.38
Integrated Clinical Case Conference	10	4.9
Gram Enteric	10	4
Pharmacokinetics	7	4.29
PSP	6	3.67
PSP	6	3.83
Pharm	13	4.92
ICC	10	4.2
ICC	10	4.1
ICC	13	4.32
Intro to Virology	13	3.92
SSRNA viruses	10	2
Vaccines	8	3.75
DNA viruses	7	4.14
Integrated Clinical Case Conference	12	4.58
Integrated Clinical Case Conference	8	3.8
Integrated Clinical Case Conference	12	4.5
Vector borne and Zoonotic Diseases	9	4.12
Intro to Hematology	13	4.38
Anemia and Red Cell Disorders	15	4.6
Myelodysplastic Syndromes	15	4.6
Acute Leukemia	14	4.7
Non Hodgkin Lymphoma	14	4.43
Hodgkin Lymphoma	14	4.5
Myeloporliferative Disease	15	4.53
Coagulation and Platelet	12	4.6
Pharmacology	11	4
ICC: Hematological Disease	10	4.1
ICC: Hematological Disease	9	4.33

Unit 1: Hematology/Immunology/Infectious Disease

Chronic HIV	11	4.27
Microbial Immune Evasion and		
Persistence	11	4
ICC: Persistne Infectious Disease	9	4.33
ICC: Persistne Infectious Disease	9	4.33
Pharm	13	4.23
Immunodeficiences	16	4.38
Effector Mechanisms of Immune Injury	15	4.47
Pharm	13	4.23
ICC: Immunodeficiency	9	4.56
ICC: Immunodeficiency	9	4.22
Average	10.93478261	4.299783

Unit 2: Cardiology/Respiratory/Renal

Торіс	Reporting	Score
Path-Kidney	8	4.38
Pharm/thrombolytics	4	4.25
PSP	4	3.75
PSP	4	3.75
PSP	3	4.33
Anticoagulants	7	2.71
CAD	3	4.33
Pathology	6	4.33
Acid/Base Pathology	5	4.4
Antiarrhythmics	3	4.33
Antiarrhythmics	3	4
Pathology	6	4.33
Peripheral Vascular Disease	5	4.4
Antihyperlipids	3	4.33
Antihyperlipids	3	4.33
Valvular Heart Disease	7	4.57
Valvular Heart Disease	5	4
Heart Failure	4	4
Heart Failure	3	4
Path: Heart Failure	7	4.57
Clincal: Smoking Cessation	5	4.2
Clincal: Smoking Cessation	5	4
Pathology	9	4.44
Clinical	5	3.8

Clinical	4	4
Clinical Pulmonary	4	3.5
Pathology	8	4.5
Pathology	7	4.14
Pathology	8	4.38
Pharmacology	6	4.33
Clinical	6	4.33
Average	5.16129	4.151935

Unit 3: Neuro/Muscle/Behavior

Торіс	Reporting	Score
Intro to Neuropharm	8	3.88
Pathology	6	4.33
Pathology	5	4.4
Pharm	4	4.5
Pharm	5	4.4
Demyelinating Disease	2	4.5
Demyelinating Disease	2	4
Demyelinating Disease	2	4
Spasticity and Neuromuscular Blockers	6	4.33
Neuro	2	3.5
Neuro	1	4
Neuro	1	4
Pathology	4	4.5
CVA Neuro	3	4.33
Pathology	6	4.33
Pharm	4	4
Coma	6	4.17
Epilepsy	3	4
Epilepsy	6	3.67
PSP	3	3.67
PSP	3	3.67
Head Trauma	0	0
Pharm	4	4.25
CNS Infection	3	4.33
Path	4	4
Path	3	4.33
Opioids, Pain, Migraine	3	4
Opioids, Pain, Migraine	3	3.67
Pharm	2	4

Pharm	2	4
Pharm	2	4.5
Pharm	1	5
Path	4	4.25
Path/Pharm	6	4.17
Path/Pharm	6	4.17
Pharm	4	3.75
Pharm	7	3.57
Psychiatirc Disorders	8	3.63
PSP	1	2
PSP	1	2
Radiology	8	3.63
Path&Pharm	4	3.75
Substance abuse	7	4.14
Substance abuse	7	4
Pharm	4	4
Pharm	4	4
Average	3.913043	3.898261

Unit 4: Endocrine/Re	eproduction/	Gastrointestinal
----------------------	--------------	------------------

Торіс	Reporting	Score
PSP: Rural Healthacare Delivery	2	5
Obestiy and Nutrition	6	4.5
Hypo/Pit	6	4.67
Hypo/Pit	5	4.6
Pancreas/Duodenum	3	4.67
Pancreas/Duodenum	3	4.67
Parathyroid	4	4.75
Parathyroid	6	4.5
Thyroid	7	4.71
Thyroid	7	4.43
Adrenals	5	4.4
Adrenals	5	4.2
Clinical Review Upper GI	4	3.75
Upper GI Pathology	7	4.29
Upper GI Pharmacology	7	4.71
Helminths	8	4.13
IDB	8	4.38
Clinical Review Lower GI	7	4.14
Lower GI Pharm	7	4.57
Lower GI Pathology	9	4.67

Diseases of Exocrine Pancreas	9	4.11
Hepatobiliary	9	4.33
СС	8	4.13
CC Clinical	7	4
CC Pathology	8	4.25
Radiology	4	4
Repro Endo Pharm	9	4.22
STI	6	4
Uterine Development	7	4.14
Uterine Development	7	3.86
Abnormal Ut Development	6	4
Infertility	10	3.9
Infertility	9	4.33
Pap Smears	8	4.13
Pap Smears	9	4.38
Gyne Onc	6	3.83
Gyne Onc Pathology	7	3.86
PSP	5	4
PSP	5	4
PSP	5	4
Pathology of Breast	9	4.22
Pregnancy	7	4
Pregnancy	6	3.67
Pregnancy	6	4
SERMS	7	4.14
Male Repro	9	3.89
Clinical Male Repro	8	3.88
Clinical Male Repro Pathology	7	4.14
Average	6.645833	4.232292